Intranasal spike and nucleoprotein fusion protein-based vaccine provides cross-protection and reduced transmission against SARS-CoV-2 variants.
Lakhrif Z, Poupée-Beaugé A, Boursin F, Ducournau C, Lantier L, Moiré N, Carpentier R, Rossignol C, Maquart M, Jospin F, Merat L, Caul-Futy M, Yazdanpanah Y, Bouakane A, Riou M, Touzé A, Eléouët JF, Richard CA, Helle F, Le Poder S, Klonjkowski B, Meunier N, Zientara S, Paul S, Mévélec MN, Aubrey N, Epardaud M, Dimier-Poisson I.
Lakhrif Z, et al. Among authors: rossignol c.
NPJ Vaccines. 2025 Apr 18;10(1):75. doi: 10.1038/s41541-025-01123-y.
NPJ Vaccines. 2025.
PMID: 40251181
Free PMC article.